Will Lowered Earnings Forecasts Shift Alkermes' (ALKS) Valuation Story or Reinforce Investor Caution?

• In recent days, analyst commentary highlighted that Alkermes plc is facing investor concerns due to a projected 21% annual contraction in earnings per share over the next three years, significantly lagging market expectations.
• This outlook has led to a low price-to-earnings ratio for Alkermes, with skepticism about whether potential improvements are enough to support a higher valuation.
• Given these lowered earnings forecasts and persistent investor caution, we'll explore how this shifts Alkermes' overall investment narrative.

These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Alkermes Investment Narrative Recap

Anyone holding Alkermes stock today needs confidence in the company’s ability to overcome declining earnings forecasts and offset near-term pressures with either pipeline progress or expanding product adoption. The recent projection of a 21% annual EPS contraction intensifies focus on the ongoing risk from one-time gross-to-net benefits, but for now, this news aligns with existing concerns and doesn’t materially alter the main short-term narrative or the risk posed by potentially weaker future revenue if those adjustments subside.

Of particular relevance is Alkermes’ July 2025 earnings announcement, where both revenue and net income slipped year over year, reinforcing investor worries reflected in the lower price-to-earnings ratio and muted expectations for earnings recovery. Against the backdrop of persistent caution around the sustainability of top-line growth, this announcement amplifies the importance of demonstrating more durable revenue drivers outside of one-off tailwinds.

In contrast, investors should also be mindful of how revenue could be pressured when the effects of these temporary adjustments fade and...

Read the full narrative on Alkermes (it's free!)

Alkermes' outlook anticipates $1.4 billion in revenue and $179.2 million in earnings by 2028. This reflects a 1.3% annual decline in revenue and a $168.9 million decrease in earnings from the current $348.1 million.

Uncover how Alkermes' forecasts yield a $41.50 fair value, a 43% upside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community estimate Alkermes’ fair value between US$41.50 and US$53.89. With earnings expected to contract further, you can see how market participants bring very different forecasts and priorities to the table.

Explore 3 other fair value estimates on Alkermes - why the stock might be worth as much as 86% more than the current price!

Build Your Own Alkermes Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Alkermes research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Alkermes research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alkermes' overall financial health at a glance.

Looking For Alternative Opportunities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com